AntaeusOne-page investor deck
Medicines for human adaptation. Bemitil is the lead. The first question is whether it preserves work capacity under heat. The program is preclinical. Human efficacy is unproven.
The one-page slide stays public. The form below records your request and provides a download of the same one-page PDF.
Leave an email so the founder can follow up. A verified submission opens a download in this browser.
Email the founder if you prefer a direct conversation.
Bemitil first. Does it preserve work capacity under heat? A preclinical drug-development program. Human efficacy is unproven.
2002 rat study (PMID 12227091): RNA-dependent antioxidant response. Indirect, mechanism unresolved.
Test molecular response alongside functional heat performance. Seek independent confirmation. Stop candidate advancement at month nine for failed replication or unacceptable safety.
$1–2M pre-seed. An illustrative $1.5M allocation funds an 18-month preclinical program: 25% for functional pharmacology / PK, 20% for molecular profiling, 15% for authenticated material and formulation, and 40% for safety, team, data, IP, and operations.
US API supply and domestic development partners are secondary goals. No US API production or government partnership is secured.
Gregory Battenfield is a merchant mariner working in heat and adverse conditions, with a banking and commodities background. He built Molekul.io: 90+ compounds and 400+ source records; founder-reported minimums, not independently verified.
No scientific lead hired. No lab contracted. No composition-of-matter IP.
investors@antaeusbiosciences.com · Full allocation and round details
1997 human heat/exertion reports (PMID 9162292, companion 9235216). Thermal tolerance and work capacity effects described; phenibut or its combination performed best; a bemitil-specific effect size is not available in the abstracts.
1991 voyage paper: +13.7% static-effort endurance, 298 operators, 20-person detailed subset, allocation unspecified, not placebo-adjusted.
2019 monograph: 86.2% vs 68.1% of baseline dynamic-endurance retention in one bemitil arm vs placebo, 78 volunteers, no arm-specific n, no randomization procedure described, no controlled heat exposure.